>NIH COVID-19 Treatment Guidelines Panel
>>15461097 DeSantis slams Biden’s ‘haphazard decision’ on monoclonal antibody treatments
What a bunch of fucking Assholes stacking the deck for stock portfolios.
NIH panel updates treatment guidelines for non-hospitalized COVID-19 patients
Alicia Lasek
January 25, 2022
>The National Institutes of Health has released a revised guideline for treating non-hospitalized patients with mild-to-moderate COVID-19 at high risk of disease progression.
Some of the recommended drugs currently are in short supply. In light of this, panelists recommended that clinicians use the following therapeutics listed in order of preference:
Ritonavir-boosted nirmatrelvir (Paxlovid);Pfizer
SotrovimabGlaxo Smith Kline(The panel does not recommend using bamlanivimab plus etesevimab or REGEN-COV.)
RemdesivirKills people with liver damage
Molnupiravirworse than remdesivir
>The results of arecent study have confirmed that sotrovimab is((( the only monoclonal antibody in clinical use that neutralizes))) the omicron variant.
https://www.nature.com/articles/s41591-021-01678-y#ethics
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Laura A. VanBlargan, John M. Errico, Peter J. Halfmann, Seth J. Zost, James E. Crowe Jr., Lisa A. Purcell, Yoshihiro Kawaoka, Davide Corti, Daved H. Fremont & Michael S. Diamond
Ethics declarations
Competing interests
M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences and Carnival Corporation and is on the Scientific Advisory Boards of Moderna and Immunome.
The Diamond laboratory has received funding support in sponsored research agreements fromModerna, Vir Biotechnology and Emergent BioSolutions.
J.E.C. has served as a consultant for Luna Biologics and Merck Sharp & Dohme, is on the Scientific Advisory Board of Meissa Vaccines and is the founder of IDBiologics.
The Crowe laboratory has received sponsored research agreements from Takeda Vaccines, AstraZeneca and IDBiologics.
Vanderbilt University has applied for patents related to two antibodies discussed in this paper.
L.A.P. and D.C. are employees of Vir Biotechnology and may hold stock shares in Vir Biotechnology.
L.A.P. is aformer employee and shareholder in RegeneronPharmaceuticals. The remaining authors declare no competing interests.